Novo Nordisk A/S’s Free Cash Flow Growth at a glance
Novo Nordisk A/S reports free cash flow growth of -0.5% for Dec 2024. The prior period recorded 9.2% (Dec 2023). Year over year the metric moved −9.7 pts (−105.5%). The rolling three-period average stands at 14.5%. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
-0.5% · Dec 2024
YoY movement
−9.7 pts (−105.5%)
Rolling average
14.5%
Current Free Cash Flow Growth
-0.5%
−9.7 pts
−105.5%
Rolling average
14.5%
Latest Value
-0.5%
Dec 2024
YoY Change
−9.7 pts
Absolute
YoY Change %
−105.5%
Rate of change
3-Period Avg
14.5%
Smoothed
Narrative signal
Novo Nordisk A/S’s free cash flow growth stands at -0.5% for Dec 2024. Year-over-year, the metric shifted by −9.7 pts, translating into a −105.5% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow growth shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports free cash flow growth of -0.5%. Gauge reinvestment strength and capital return capacity using free cash flow growth over multiple reporting periods.
Cash flow versus earnings
Free cash flow growth can diverge from earnings due to working capital and capex swings. Track both to confirm quality.
Capital allocation insights
Rising free cash flow enables dividends, buybacks, and debt reduction—key levers for shareholder value.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
84.7%
Operating Margin
44.2%
Net Profit Margin
34.8%
Return on Equity
70.4%
Return on Assets
21.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s free cash flow growth profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current free cash flow growth?
As of Dec 2024, Novo Nordisk A/S reports free cash flow growth of -0.5%. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's free cash flow growth trending year over year?
Year-over-year, the figure shifts by −9.7 pts (−105.5%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does free cash flow growth matter for Novo Nordisk A/S?
Free cash flow growth measures how quickly operating cash surplus expands compared with the prior period. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's free cash flow growth above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 14.5%. Comparing the latest reading of -0.5% to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's free cash flow growth refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.